{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:13:58Z","timestamp":1793909638038,"version":"4.8.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32DA007027"],"award-info":[{"award-number":["T32DA007027"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA055825"],"award-info":[{"award-number":["R01DA055825"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The present study determined the effectiveness of the glucagon-like peptide 1 agonist semaglutide to attenuate cocaine-vs-food choice in male and female rats. Repeated 5-day semaglutide treatment decreased cocaine choice and significantly reduced body weight. These preclinical results support the clinical evaluation of semaglutide as a candidate cocaine use disorder medication.<\/jats:p>","DOI":"10.1038\/s41386-026-02386-2","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:24:19Z","timestamp":1776266659000},"page":"1144-1146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Repeated semaglutide treatment attenuates cocaine-vs-food choice in male and female rats"],"prefix":"10.1038","volume":"51","author":[{"given":"Nicholas","family":"Heslep","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4949-5246","authenticated-orcid":false,"given":"Matthew L.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2386_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40429-025-00657-4","volume":"12","author":"L Yammine","year":"2025","unstructured":"Yammine L, Grigson PS, Schmitz JM, Evans BB, Hendershot CS. The Potential Utility of GLP-1 Receptor Agonist Medications for Addiction Treatment: A Narrative Review of Clinical and Epidemiological Evidence. Curr Add Rep. 2025;12:59.","journal-title":"Curr Add Rep"},{"key":"2386_CR2","doi-asserted-by":"publisher","first-page":"e69010","DOI":"10.1371\/journal.pone.0069010","volume":"8","author":"E Egecioglu","year":"2013","unstructured":"Egecioglu E, Engel JA, Jerlhag E. The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice. PLOS ONE. 2013;8:e69010.","journal-title":"PLOS ONE"},{"key":"2386_CR3","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/mp.2012.141","volume":"18","author":"DL Graham","year":"2013","unstructured":"Graham DL, Erreger K, Galli A, Stanwood GD. GLP-1 analog attenuates cocaine reward. Mol Psychiatry. 2013;18:961\u201362.","journal-title":"Mol Psychiatry"},{"key":"2386_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euroneuro.2025.07.001","volume":"98","author":"C Aran\u00e4s","year":"2025","unstructured":"Aran\u00e4s C, Caffrey A, Edvardsson CE, Schmidt HD, Jerlhag E. Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens. Eur Neuropsychopharmacol. 2025;98:1\u201310.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2386_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr5051","volume":"11","author":"R Merkel","year":"2025","unstructured":"Merkel R, Hernandez NS, Weir V, Zhang Y, Caffrey A, Rich MT, et al. An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Sci Adv. 2025;11:eadr5051.","journal-title":"Sci Adv"},{"key":"2386_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","volume":"149","author":"G S\u00f8rensen","year":"2015","unstructured":"S\u00f8rensen G, Reddy IA, Weikop P, Graham DL, Stanwood GD, Wortwein G, et al. The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice. Physiol Behav. 2015;149:262\u201368.","journal-title":"Physiol Behav"},{"key":"2386_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108614","volume":"221","author":"GA Angarita","year":"2021","unstructured":"Angarita GA, Matuskey D, Pittman B, Costeines JL, Potenza MN, Jastreboff AM, et al. Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder. Drug Alcohol Depend. 2021;221:108614.","journal-title":"Drug Alcohol Depend"},{"key":"2386_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2021.173264","volume":"210","author":"SS Negus","year":"2021","unstructured":"Negus SS, Banks ML. Confronting the challenge of failed translation in medications development for substance use disorders. Pharmacol Biochem Behav. 2021;210:173264.","journal-title":"Pharmacol Biochem Behav"},{"key":"2386_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107312","volume":"207","author":"N Bruns Vi","year":"2024","unstructured":"Bruns Vi N, Tressler EH, Vendruscolo LF, Leggio L, Farokhnia M. IUPHAR review \u2013 Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target. Pharmacol Res. 2024;207:107312.","journal-title":"Pharmacol Res"},{"key":"2386_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41587-025-02644-6","volume":"43","author":"C Sheridan","year":"2025","unstructured":"Sheridan C. Not just obesity: GLP-1 receptor agonists advance on addiction. Nat Biotechnol. 2025;43:455\u201357.","journal-title":"Nat Biotechnol"},{"key":"2386_CR11","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/npp.2016.259","volume":"42","author":"ML Banks","year":"2017","unstructured":"Banks ML, Negus SS. Repeated 7-Day Treatment with the 5-HT2C Agonist Lorcaserin or the 5-HT2A Antagonist Pimavanserin Alone or in Combination Fails to Reduce Cocaine vs Food Choice in Male Rhesus Monkeys. Neuropsychopharmacology. 2017;42:1082\u201392.","journal-title":"Neuropsychopharmacology"},{"key":"2386_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.111063","volume":"255","author":"DJ McCann","year":"2024","unstructured":"McCann DJ, Chen HH, Devine EG, Gyaw S, Ramey T. Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder. Drug Alcohol Depend. 2024;255:111063.","journal-title":"Drug Alcohol Depend"},{"key":"2386_CR13","doi-asserted-by":"crossref","unstructured":"Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-R\u00f8nne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5:e133429.","DOI":"10.1172\/jci.insight.133429"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02386-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02386-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02386-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:42:52Z","timestamp":1779806572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02386-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2386"],"URL":"https:\/\/doi.org\/10.1038\/s41386-026-02386-2","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that no actual or perceived conflicts of interest exist.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}